Category: Vaccine

Page 48«..1020..47484950..6070..»

Driving delivery and uptake of catch-up vaccination among adolescent and adult migrants in UK general practice: a … – BMC Medicine

May 3, 2024

Study design and procedure

We conducted a prospective, observational mixed-methods pilot study from May 2021-September 2022 in seven GP practices across two urban London boroughs. The study was designed as a pilot to test processes and approaches which may inform a future large-scale study or trial. The overall objectives were to measure routine vaccination coverage among migrants presenting to UK primary care and establish and test new referral pathways for catch-up vaccination. The study procedure was as follows: following recruitment, participants were asked about their vaccination history (including for routine childhood immunisations including MMR, Td/IPV, and other vaccines including tuberculosis/bacille Calmette-Guerin vaccine (TB/BCG) and HPV), which was coded into their electronic patient record and the study database. In the absence of a written vaccination card or record documenting a completed vaccine course, or if patients said they had not had a vaccine or were unsure, patients were referred for catch-up vaccination for each eligible vaccine (following the UK algorithm for vaccinating individuals with uncertain or incomplete immunisation status [21]) and invited to attend an appointment(s) with their practice nurse. Eligible catch-up vaccines were MMR, Td/IPV, HPV (aged 1125 years) and MenACWY (aged 1025 years). Practice nurses followed the UK algorithm to administer missing vaccine doses, boosters, and courses and recorded the data into the patients electronic record and the study database. A standardised data collection tool was designed to facilitate the collection of data, which then prompted referrals for catch-up vaccination (see Data collection and referral pathway for catch-up vaccination).

PICOTS criteria for the study are shown in Table 1. In addition to collecting quantitative data from migrant patients, we explored the views of practice staff on catch-up vaccination and current guidance, including barriers to implementation, suggestions, and areas for improvement and support, through focus group discussions (FGDs), which were carried out in August 2022. During the study, we also decided to conduct an in-depth interview with two staff members to explore examples of good practice from the most successful (in terms of recruitment and uptake) participating practice. We carried out in-depth interviews with a diverse range of recently arrived (10 years) migrants to explore views and concerns around catch-up vaccination after arrival in the UK. The study tool, recruitment, and data collection pathways are shown in Fig. 1. The reporting of this study follows the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [22].

This study received ethics approval from the NHS Health Research Authority Yorkshire and HumberSouth Yorkshire Research Ethics Committee (20/YH/0342) on 18 December 2020. The qualitative in-depth interview study with migrants received ethics approval from the St Georges, University of London Research Ethics Committee (REC reference: 2020.0058). Migrants with lived experience of the UK immigration and healthcare systems were involved in the design of this study through our National Institute for Health and Care Research (NIHR)-funded Patient and Public Involvement and Engagement (PPIE) Project Advisory Board and were compensated for their time and contributions.

The study was conducted with support from the NHS North Central London Research Network (NoCLoR) and the North Thames Clinical Research Network (CRN). GP practices in areas with a high proportion of migrant residents were purposively invited to join the study. We aimed to recruit up to 10 GP practices across two boroughs (Barnet and Tower Hamlets) in North and East London (referred to henceforth as sites 1 and 2), with a target sample size of 100 participants. Boroughs were selected for their high proportion of migrant residents (estimated to be approximately half, according to 2021 Census data [23]). Both rank in the top 50% of most deprived local authorities in England, based on the English indices of deprivation 2019 [24], although Tower Hamlets ranks as significantly more deprived than Barnet. In practice, seven GP practices were recruited, with six across site 1 and one practice belonging to site 2.

Patients registered at participating practices were eligible for the study if they were (a) aged 16 years or older, (b) born outside of the UK (our migrant definition excluded those born in North America, Australia, New Zealand, or Western Europe, as defined by the UN maximal definition of Western Europe [25]), and (c) capable of giving informed consent. Recruitment procedures differed between the two sites (see Fig. 2).

Figure showing standardised data collection tool (left) and referral pathways implemented in study sites 1 and 2 (right). VPDs, vaccine-preventable diseases; PN, practice nurse; HCA, healthcare assistant; CRN, clinical research network

We held site initiation visits with all practice sites, inviting GPs, practice managers, healthcare assistants (HCAs), and nurses involved in immunisation. Alongside delivering training on the current UK primary care catch-up vaccination guidelines [21] and the referral pathway to implement upon identifying under-vaccinated patients, these visits covered the study processes and procedures, approaches to identifying the study population and recruiting participants, and use of the standardised data collection tool.

At site 1 (n=6 GP practices), clinical practice staff were originally going to recruit and consent patients. However, the recruitment pathway was modified as clinical staff were under intense pressure from the COVID-19 pandemic, so the CRN led the recruitment and consenting process. Practice nurses and HCAs first identified patients who met the eligibility criteria, filtering patient records by ethnicity or notes on migrant status (where recorded) to identify those potentially eligible and sent an SMS/text message with a link to the study website, from which patients could download the study documents (participant information sheet [PIS], consent form, and leaflets about catch-up vaccination and HPV vaccination, all available in the six dominant local languages, which were Arabic, Farsi, Pashtu, Romanian, Urdu, English). A researcher at the CRN (DF) then followed up with patients by a telephone call enquiring whether they would like to join the study and to take informed consent. Practice nurses also mentioned the study opportunistically to patients during routine appointments, who would then be referred to the CRN researcher (DF) for consent. At site 2 (n=1 GP practice), the practice nurses HCAs invited and consented participants to the study opportunistically during routine appointments, as per the original recruitment pathway. Participants were given hard copies of the study documents and given the opportunity to ask questions and decide whether they wanted to participate. We gave practice and CRN staff a copy of a form detailing the names of common childhood vaccines in multiple languages, to support taking vaccine history during appointments (see Supplementary files). Telephone interpreters (via Language Line) were available on request at both sites during recruitment and data collection.

We developed a standardised data collection tool using Microsoft Excel, which was used to collect specific sociodemographic information (such as country of birth, which is not routinely recorded in patient records), immunisation history, and monitoring and uptake data when patients were referred for catch-up vaccination (Fig. 2). We documented participants rates of under-vaccination for MMR, Td/IPV, and other key vaccines in the UK routine immunisation schedule, history of VPDs, and uptake rates of MMR, Td/IPV, MenACWY, and HPV vaccines following referral to the practice nurse for catch-up vaccination. We also explored sociodemographic factors associated with under-vaccination in the study population. Immunisation history was based on self-reporting or vaccination records (via the primary care computer system or hand-held vaccination cards) where available.

Data collection and referral pathways and procedures differed between sites and are outlined in Fig. 2. In site 1, the CRN researcher collected core data via telephone call with the participant, which were recorded in the patients electronic medical record and on the password-protected study database. The CRN researcher determined the participants need for catch-up vaccinations based on the study training and the UK catch-up vaccination guidelines [21] and, if accepted by the participant, contacted the practice nurse (at the practice where the patient was registered) to arrange an appointment. Once the CRN staff had facilitated an appointment for first doses, they then left practice nurses to follow-up patients for subsequent doses as per routine care. Subsequent catch-up vaccination doses (uptake data) were recorded by practice staff in the patients medical record at the time of administration and these data were later extracted by the CRN researcher (see Data management, follow-up, and statistical analysis). In site 2, the practice nurse collected core data (recorded in the patients medical record) during face-to-face appointments, administered first doses where vaccine stocks allowed, and booked patients for any necessary follow-up appointments for catch-up vaccinations and subsequent doses. Anonymised study data (core, monitoring and uptake data) were extracted from electronic patient records by the practice manager at site 2 and securely transferred to the CRN researcher, who added them to the aggregate study database.

We aimed to follow-up patients for a minimum of 6 months at both sites to allow for all doses (Td/IPV is 3 doses, with a 4-week gap in between each; Fig. 1). At the end of follow-up, the CRN researcher securely extracted monitoring and outcomes data from participants electronic medical records and updated the aggregate study database. A de-identified, anonymised version was then transferred securely to the study team at St Georges for data cleaning and analysis.

Data cleaning and analyses were done using STATA 12. All tests were two-tailed and p values less than 0.05 were regarded as significant. We used descriptive statistics to describe the sociodemographic characteristics, vaccination history, VPD history, and catch-up vaccine uptake of participants. We summarised continuous data with mean and standard deviation (SD) and described categorical responses using the frequency and percentage. Comparisons between categorical variables were calculated using Pearsons chi-squared test, and comparisons between continuous variables were calculated using unpaired t-tests.

Bivariable and multivariable logistic regression analyses were chosen to model the relationship between a binary outcome and predictor variables and were used to look for factors associated with being un-vaccinated (received zero doses) or under-vaccinated (received at least 1 dose, but not full schedule) for key vaccines at the time of study enrolment. Outcomes included un-vaccinated for MMR vaccine, un-vaccinated for Td/IPV vaccine, un-vaccinated for MMR vaccine and Td/IPV vaccine, unvaccinated for any poliocombined or single vaccines, unvaccinated for any measlescombined or single vaccines, and under-vaccinated for MMR vaccine or Td/IPV vaccine. Explanatory variables were age, sex, birth region, region lived prior to the UK, years in the UK, and study site (migration reason and occupation were only recorded in site 1 and were therefore not included in the regression analyses). Multivariable models were built in a forward, stepwise fashion. Age, sex, and birth region were adjusted for in each multivariable model; certain variables were removed from the final model to reduce collinearity.

Our qualitative component included FGDs and an in-depth interview conducted with practice staff from participating practices and in-depth interviews conducted with recently arrived migrants. Topic guides were developed by the research team. The interviews with migrants were done remotely (either over the phone or through video call) across 17 months. Migrant participants were recruited using purposive and snowball sampling, with the aim of recruiting participants from a broad range of nationalities, migration statuses, and age groups. Adverts for the study and participant information sheets were circulated to 20 UK-based migrant support groups (mostly based in South London and chosen for their locality around St Georges, University of London) and on social media. Those who expressed an interest in taking part were contacted by telephone, and the study was explained to them with interpreters available on request. Translated participant information sheets were circulated, and written informed consent was obtained from all participants prior to carrying out an interview (methods reported in full elsewhere [26]). We did three FGDs which were scheduled to take place at the end of routine practice meetings conducted on Microsoft Teams (most convenient for participants). Participants were practice nurses, HCAs, and practice managers (roles involved in vaccination delivery/scheduling) from the participating practices. An in-depth interview was conducted with two staff from site 2 (due to timing, these staff had not participated in FGDs). For the FGDs, all staff received information about the study and how their data would be used in advance, which was reiterated at the start of the meeting, and staff were able to make an informed decision about their participation. Participants were asked to imply consent by remaining on the call, which was considered appropriate because the topic was low risk, not audio recorded, and anonymised summary feedback (broad views) was collected. All participants received a PIS and provided written informed consent prior to participating. Both the FGD and staff interviews followed a semi-structured topic guide, which explored participants experiences of implementing the study, current barriers and challenges to delivering catch-up vaccinations, and suggestions for improving the tool, referral pathways, and engaging migrant patients/promoting catch-up vaccination among these groups. Broad views and selected short-hand quotations (non-attributable) were collected during FGDs in the form of hand-written and typed notes (by SH and LPG). The staff interview was conducted by AFC with two staff participants in a private room, audio-recorded and transcribed verbatim by a professional transcription service.

Qualitative data were analysed deductively using a flexible and rapid thematic analysis and evaluation approach [27]. Notes from the FGDs which were reflected on and discussed afterwards by AFC, SH and LPG, and AFC then independently coded and grouped the findings into broad barrier and facilitator concepts using a matrix method (by hand and in Microsoft Excel). The data in the matrix were corroborated and discussed again by the three researchers, to ensure rigour and coding reliability. The same approach was used to analyse the transcript of the key informant interview. Migrant interviews were analysed using the thematic framework approach in NVivo 12. Triangulation occurred when the qualitative and quantitative data were combined but also by the interaction between the three researchers during data collection and analysis and through the contributions of their own perceptions, beliefs, and academic disciplines to the collection and interpretation of data.

See the rest here:

Driving delivery and uptake of catch-up vaccination among adolescent and adult migrants in UK general practice: a ... - BMC Medicine

Rotavirus vaccination not tied to NICU outbreaks, researchers say – University of Minnesota Twin Cities

May 3, 2024

Erskine Palmer / CDC

The benefits of vaccinating vulnerable preterm infants in the neonatal intensive care unit (NICU) against diarrhea-causing rotavirus outweigh the risks, according to a USstudy being presented this weekend at the Pediatric Academic Societies (PAS) 2024 Meeting in Toronto.

The finding that rotavirus vaccination doesn't cause significant hospital outbreaks is important because many NICUs don't give the vaccine because of fears of viral transmission (the vaccine contains a weakened form of rotavirus), and some babies are too old to receive it after NICU release, researchers from the Children's Hospital of Philadelphia (CHOP) said in a PAS news release.

The researchers assessed the risk of vaccinated infants spreading highly contagious rotavirus to unvaccinated babies in NICUs that administer the vaccine. They analyzed 3,448 weekly stool samples from 774 newborns from January 2021 to January 2022.

Less than 1% of unvaccinated infants exposed to vaccinated babies contracted rotavirus, and their symptoms resolved after 2 weeks.

Read the original:

Rotavirus vaccination not tied to NICU outbreaks, researchers say - University of Minnesota Twin Cities

What We’re Reading: Bird Flu Vaccines; Walmart Health Shut Down; Arizona Repeals Abortion Ban – AJMC.com Managed Markets Network

May 3, 2024

US Readies Vaccines for Potential Spread of Bird Flu Among Humans

Amid concerns over a strain of bird flu circulating in dairy cows potentially spreading to humans, US federal health officials have announced readiness to deploy vaccines should the need arise, according to NBC News. Although there's currently no evidence of person-to-person transmission, preparations are underway given the virus' prevalence in dairy herds across several states. Vaccine candidates are already available, with plans to ship hundreds of thousands of doses within weeks if the situation escalates.

Walmart to Close Health Centers Amid Retail Health Challenges

Walmart's decision to close its Walmart Health centers in 5 states, along with its virtual care services, reflects the significant challenges retail players face in disrupting primary care, according to Fierce Healthcare. The closure of all 51 health centers underscores issues related to sustainability, profitability, and operational costs. This move has marked a dramatic shift from the retailer's earlier plans to expand its health care footprint, aligning with similar struggles faced by other retailers like Walgreens as they scale back their primary care clinic chains.

Arizona Lawmakers Repeal Civil WarEra Abortion Ban Amid Political Fallout

Arizona lawmakers voted to repeal the state's long-standing Civil Warera abortion ban, according to Politico. The repeal preserves access to abortion for millions of women and marks a significant shift from previous efforts to uphold the 1864 ban. Democrats had been leveraging the ban to rally support ahead of the November election, but Republicans, fearful of electoral consequences, ultimately joined Democrats in passing the repeal.

Original post:

What We're Reading: Bird Flu Vaccines; Walmart Health Shut Down; Arizona Repeals Abortion Ban - AJMC.com Managed Markets Network

Switzerland eradicated rabies by air dropping chicken heads! – The Times of India

May 3, 2024

In the late 20th century, Switzerland faced a formidable public health challenge: rabies. This deadly virus, primarily transmitted through the bites of infected animals, poses a significant threat to both wildlife and humans. The Swiss authorities, determined to combat the disease, devised an innovative and unconventional strategy: air-dropping vaccine-laced chicken heads across the countrys forests and countryside. The operation was set against the backdrop of a Europe grappling with rabies outbreaks, particularly in wild fox populations. Switzerlands approach was groundbreaking. In the 1960s and 1970s, the countrys Federal Veterinary Office ordered that chicken heads stuffed with vaccine be placed on the ground in high-risk areas. This method was not only inventive but also effective, marking the beginning of a campaign that would eventually lead to the eradication of rabies in Switzerland. The bait, designed to attract foxes, was laced with a vaccine that, once ingested, would immunize the animal against rabies. The strategy relied on the natural behavior of foxes to scavenge for food, thus ensuring the vaccines distribution among the target population. The use of aerial distribution methods allowed for a wide coverage area, reaching even the most remote and inaccessible regions where foxes roamed. This method of vaccination was a departure from traditional approaches, which often involved trapping and inoculating individual animalsa labor-intensive and less efficient process. By contrast, the Swiss method allowed for mass vaccination of wildlife without the need for direct human-animal contact, significantly reducing the risk of transmission to veterinarians and wildlife officers.

Expand

Representative image

View post:

Switzerland eradicated rabies by air dropping chicken heads! - The Times of India

Why flu vaccines are needed before summer ends and rainy season begins? – Hindustan Times

May 3, 2024

As the flu season approaches, experts are advocating annual Influenza vaccination for all children aged 6 months to 5 years of age as it is a known fact that the symptoms of influenza virus and Covid-19 tend to mimic each other, leading to fear and anxiety among parents of young children. The flu shot acts as a vital defense, significantly reducing the risk of influenza-related complications in children so, read on as we help you to understand the importance of flu vaccination for children before monsoon.

In an interview with HT Lifestyle, Dr Anish Pillai, Lead Consultant- Neonatology and Paediatrics at Motherhood Hospitals in Kharghar and Navi Mumbai, shared, Even though monsoon is known to provide that much-needed relief from the scorching summer heat, it is known to set the stage for a plethora of health problems, one of them being the common cold or flu infection. Flu cases in children are common in every household during the rainy season. Thus, managing a child with runny nose, cough, and fever has become a part and parcel of a parents life.

Dr Anish Pillai answered, Influenza or flu is a contagious viral infection that takes a toll on the airways and lungs of a child and is the most common respiratory illness seen in children during monsoon. Flu leads to discomfort, and school absenteeism in children and impacts their quality of life. Also, some children may encounter severe symptoms such as breathlessness, hypoxia, irritability, and decreased appetite, requiring hospital admission. The flu virus spreads through the droplets released when a patient with flu tends to cough, sneeze or even talk. Hence, by being around an infected person, one can be at a greater risk of acquiring the flu.

He explained, The droplets in the air can spread up to about 7 feet away and reach others who are in the vicinity. So, for kids going to daycare or school, the monsoon season becomes a constant cycle of repeated flu infections and recovery. The flu vaccine not only protects the child but also shields those around them, including older family members and classmates. Flu vaccines are meticulously developed each year to target prevalent strains, ensuring best protection. The traditional flu shot contains inactivated (killed) flu viruses (influenza A and B), making it extremely safe and efficacious.

Dr Anish Pillai elaborated, Parents should not skip the flu vaccination fearing side effects, as they are minimal in the form of fever, headache and swelling for a day or two at the injection site. Getting vaccinated against Influenza annually will boost immunity and prevent severe symptoms or complications. So, parents, what are you waiting for? Schedule an appointment with the Pediatrician today and get your child vaccinated without any further delay to help him/her have a healthy monsoon. Other measures: To prevent flu, parents should teach children to cover their mouth and nose while coughing/ sneezing, wash hands regularly, maintain a safe distance from people, wear a mask if unwell, avoid crowded places or being around sick people and eat a nutritious diet to boost immunity.

Catch your daily dose of Fashion, Taylor Swift, Health, Festivals, Travel, Relationship, Recipe and all the other Latest Lifestyle News on Hindustan Times Website and APPs.

See original here:

Why flu vaccines are needed before summer ends and rainy season begins? - Hindustan Times

Dose-sparing mpox vaccine regimen is safe and effective – PharmaNewsIntel

May 3, 2024

May 03, 2024 -Research presented at the European Society of Clinical Microbiology and Infectious Diseases Global Congress in Barcelona on April 27, 2024, revealed that a dose-sparing mpox vaccine regimen offered the same antibody response as the standard protocol at six weeks, deeming the dose-sparing method as safe and effective.

While mpox originated in West, Central, and East Africa, with the first human cases identified in the 1970s, a recent resurgence of the virus in May 2022 presented a global threat. The 2022 outbreak was tied to the clade IIb strain of the virus, impacting communities far beyond the historically affected regions.

Rapid efforts from the biopharmaceutical industry and FDA helped address this epidemic by approving a mpox vaccine: the Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN, sold as JYNNEOS) vaccine. The vaccine is a two-dose series given four weeks apart, with maximum protection occurring two weeks after the final vaccine. The CDC recommends the vaccine for certain populations at greater risk of contracting the virus, including men who have sex with men (MSM) and transgender, gender non-binary, or gender-diverseindividuals who have had one or more sexually transmitted infections or more than one sexual partner in the past six months. However, much like other highly demanded pharmaceutical products, the mpox vaccines are in short supply.

To address the supply chain issues, the National Institute of Allergy and Infectious Diseases (NIAID), a subset of the NIH, sponsored a study that explored dose-sparing vaccine regimens to extend the existing supply.

The study recruited 225 adults between 18 and 50 years who were not vaccinated against mpox or smallpox across the United States. The randomized study assigned some participants to receive the FDA-approved vaccine regimen, one-fifth of the standard dose or one-tenth of the standard dose. The standard dose was delivered subcutaneously, while the dose-sparing alternatives were injected intradermally. All patients received a two-dose series 28 days apart.

Two weeks after the second dose, those given one-fifth of the standard dose had antibody levels that were comparable to those of the FDA-approved regimen. However, those who received one-tenth of the dose did not have similar benefits.

The NIH press release concluded that because there are no defined correlates of protection against mpox immune processes confirmed to prevent disease these findings cannot predict the efficacy of dose-sparing regimens with certainty. Real-world data from the Centers for Disease Control and Prevention and others have shown similar vaccine effectiveness for the dose-sparing regimen given intradermally and the standard regimen given subcutaneously. A study of the standard MVA-BN regimen in adolescents is ongoing and will report findings later this year.

More:

Dose-sparing mpox vaccine regimen is safe and effective - PharmaNewsIntel

Fact Check: Are Indians Who Got Covishield Vaccine Susceptible To TTS? – NDTV

May 1, 2024

New Delhi:

AstraZeneca, which developed and manufactured the Covid vaccine Covishield. recently admitted that the vaccine could cause TTS (a condition that may cause blood clots and low platelet count) as a side effect in some people. Since the news came out, social media has been abuzz with posts about Covishield, which was one of the two vaccines available in India during the pandemic. Some of these posts claim most Indians are at risk of TTS now. A fact check by The Healthy Indian Project (THIP) indicates that the claim is only half true. While the risk of TTS is true, the probability is "very rare".

The Claim

The Indian government has been blamed in multiple social media posts for allowing the Covishield vaccine in the country and putting people at risk for vaccination-induced Thrombosis with Thrombocytopenia Syndrome (TTS). This allegation stems from AstraZeneca's acknowledgment in UK court about the fact that their vaccines can cause rare side effects. One such post blaming the Indian government can be seen below:

Fact Check

What is TTS? What are its symptoms?

Thrombosis with Thrombocytopenia Syndrome (TTS) is a serious health condition that causes low platelet count (thrombocytopenia) and clots blood (thrombosis) within the body. The condition is linked to adenovirus vector vaccines launched during Covid-19.

The noted symptoms of the condition range from shortness of breath, chest pain, leg swelling, severe and continuous headaches, and stomach aches. Affected persons suffer from easy bruising.

Do AstraZeneca Covid vaccines cause Thrombosis with Thrombocytopenia Syndrome (TTS)? Yes, but as a rare side effect. It is important to understand that as stated by the company and proven by earlier research, not everyone who was administered Astra Zeneca Covid vaccines will be affected with TTS.

The multinational pharmaceutical corporation AstraZeneca has admitted that its COVID-19 vaccine, AZD1222, may lead to a rare occurrence of decreased platelet levels and blood clot formation. AstraZeneca has acknowledged a connection between the vaccine and Thrombosis with Thrombocytopenia Syndrome (TTS), a medical condition distinguished by unusually low platelet levels and the development of blood clots. This statement comes in answer to lawsuits filed against the company in UK court. This is the same vaccine that is manufactured under the name Covishield in India.

The company has mentioned in its legal papers that though there is a chance for TTS to occur, it is "rare" and "uncommon".

How do Covishield and AstraZeneca relate to each other?

AstraZeneca, a British-Swedish pharmaceutical company, developed the COVID-19 vaccine in collaboration with Oxford University. The same vaccine is licensed for manufacture by the Serum Institute of India under the brand name Covishield. In Europe, the vaccine is sold under the brand name Vaxzevria. In short, both vaccines are identical in their formulation but are manufactured and distributed in different geographies.

AstraZeneca's vaccine is categorised under the adenovirus vector vaccine. Based on clinical trials, both of these vaccinations show 6080% protection against COVID-19 infection beginning two weeks following the second dosage.

Is the AstraZeneca vaccine the only vaccine related to Thrombosis with Thrombocytopenia Syndrome (TTS)?

No. TTS is linked to other Covid vaccines too. Johnson & Johnson's Covid vaccine named Janssen has also been linked with the condition. In 2023 World Health Organization (WHO) noted TTS as an adverse effect to adenovirus vector-based vaccines.

In a 2023 report by Yale Medicine hematologist Robert Bona, MD, explained, "Those clots typically occur in individuals who are bedridden, hospitalized, or have other medical issues related to inflammation, infection, or cancer."

So, the current revelation is not completely new.

Is the Covishield-vaccinated Indian population at risk of acquiring TTS?

A little. But there is still no reason to panic.

It should be made clear that Covishield, the Indian version of AstraZeneca, is the most widely administered Indian vaccine. There have been a limited number of cases of TTS so far reported across the country in the last few years. If there were large-scale deaths due to TTS resulting from vaccination, it surely would have been noticed and reported in the media.

It also needs to be understood that Thrombosis with Thrombocytopenia syndrome (TTS), including vaccine-induced immune thrombotic thrombocytopenia (VITT), is an extremely rare side-effect mostly seen post-initial vaccination. Earlier research has also shown that other vaccine-induced complications like CVST, have not yet been documented in India despite the widespread use of Covishield.

Vaccinations have been demonstrated to be highly effective and safe in halting the COVID-19 pandemic; however, there is a remote chance of rare adverse effects such as TTS and VITT. Early diagnosis and prompt intervention are key for patient management. It should be emphasized that the safety profiles of the vaccines are meticulously monitored by the regulatory authorities.

Saying that all Indians are at risk of dying due to Thrombosis with Thrombocytopenia syndrome (TTS) and that it has been a government failure, is an exaggeration of the entire situation and misleading.

The Healthy Indian Project (THIP) is a member of the World Health Organization's Vaccine Safety Net (VSN) and provides accurate information about vaccines. We have already fact-checked the accuracy of several COVID-19 vaccination-related claims that have been circulated on social media. These mostly include the claims that vaccines are poisonous, harmful to the brain, and more damaging than preventive.

Are side-effects common with all vaccines?

Yes. Mild side effects are not very uncommon for most vaccines. But these side effects like fever and pain are temporary. In the case of vaccinations, most medical professionals believe the side effects are far lesser compared to the benefits the vaccines provide.

As per the website of the World Health Organization (WHO), "Vaccines are very safe. Like any medicine, vaccines can cause side effects. However, these are usually very minor and of short duration, such as a sore arm or a mild fever. More serious side effects are possible but extremely rare".

Should you be concerned if you are vaccinated with Covishield?

No. As of now, there is no reason to panic.

Dr. Jayadevan, Co-Chairman of the National Indian Medical Association (IMA) Covid Task Force in Kerala, told ANI, "It's a rare occurrence following specific types of vaccines and other causes." Also, in rare cases when TTS is reported, it is mostly within a few weeks of vaccinations. So, stay vigilant and consult a doctor in case you face any of the symptoms of TTS.

(This story was originally published by THIP Media, and republished by NDTV as part of the Shakti Collective.)

Original post:

Fact Check: Are Indians Who Got Covishield Vaccine Susceptible To TTS? - NDTV

China ousts chief scientist for COVID vaccine, citing corruption – Business Insider

May 1, 2024

Angle down icon An icon in the shape of an angle pointing down. Yang Xiaoming speaks during 2020 Zhongguancun (ZGC) Forum on September 18, 2020 in Beijing, China. Hou Yu/China News Service via Getty Images

The chief researcher of China's first general-use COVID vaccine was ousted last week from the country's highest organ of power.

Yang Xiaoming, 62, was booted on April 23 from the National People's Congress "due to serious discipline and law violations," state media reported this weekend.

The phrase typically means a person is under investigation for corruption in China.

That means Yang, the chairman of Sinopharm's vaccine subsidiary China National Biotec Group, is no longer one of the nearly 3,000 congressional deputies who make decisions on major national issues.

A congressional report on his dismissal said he served on the Ethnic Affairs Committee.

Yang is a medical researcher who led the Sinopharm team that developed the BBIBP-CorV vaccine, a COVID-19 shot that was the nation's first approved for general use.

Known colloquially as the Sinopharm vaccine, the shot was one of the most widely administered COVID-19 shots in China, with an efficacy of 79% against hospitalization.

Apart from developing the Sinopharm shot, Yang was also the head of China's vaccine project under the 863 program, or Beijing's push to make the country more independent by developing homegrown advanced technologies.

Yang's dismissal has gone viral on Weibo, China's version of X, with thousands of posts questioning the circumstances behind his removal from deputy status. It received around 180 million views and, for several hours, was the platform's hottest topic on Sunday.

The discussion soon morphed into wild speculation that the reason behind his dismissal may have been related to the Sinopharm vaccine, though there has been no evidence to indicate as such.

"The father of the Sinopharm vaccine violated regulations and laws, but it doesn't mean there are problems with the vaccines he developed and produced," wrote "Dr Chen," a popular medical blogger. "Let's wait before panicking."

The announcement about Yang comes amid China's sweeping crackdown on corruption in its healthcare sector, with investigations launched against hundreds of hospital deans and secretaries.

It's been the heaviest disciplinary campaign ever enforced on China's healthcare industry, plagued for years by thousands of commercial bribery cases between pharmaceutical suppliers and healthcare providers.

In August, the anti-corruption campaign caused pharmaceutical A-share stocks in China to fall so sharply that it wiped out an estimated $27 billion market value within one day.

Continue reading here:

China ousts chief scientist for COVID vaccine, citing corruption - Business Insider

AstraZeneca admits its COVID vaccine, Covishield, can cause rare side effect – The Times of India

May 1, 2024

Expand

In 2023, the World Health Organisation (WHO) said in its report that TTS emerged as a new adverse event following immunisation in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines. This refers to the AstraZeneca COVID-19 ChAdOx-1 vaccine and the Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccines.

Read more from the original source:

AstraZeneca admits its COVID vaccine, Covishield, can cause rare side effect - The Times of India

Pfizer takes top spot in docs’ vaccine ranking by ‘huge margin’ – FiercePharma

May 1, 2024

Physicians are unequivocal about who is the big kahuna in the vaccine industry. Asked to rank vaccine manufacturers on five metrics, physicians produced a leaderboard that reads Pfizer, yawning gap, Merck.

ZoomRx generated the ranking by asking 50 physicians to name the top vaccine manufacturers in five areas: reputation, innovation, patient centricity, promotions and HCP centricity. The doctors ranked 13 vaccine manufacturers, but the same name kept appearing toward the top of their lists, regardless of the metric being assessed.

Around 80% of respondents ranked Pfizer as one of the top three companies in every category. Merck came closest to keeping pace with Pfizer but was still a long way back. The closest Merck got to Pfizer was in the innovation and patient centricity categories, where the front-runner had a 23 percentage point lead over second place.

Pfizer leads by a huge margin across all metrics, ZoomRx wrote in its assessment of the results. Their quick response to the pandemic with the COVID-19 vaccine is still holding high regards and recognition.

As ZoomRx noted, Pfizers vaccine team followed up its pandemic success with three launches last year. The Big Pharma entered the nascent respiratory syncytial virus (RSV) space with Abrysvo, added Prevnar 20 to its successful pneumococcal franchise and broke new ground with its meningitis vaccine Penbraya. Pfizers CEO bemoaned the bad launch of Abrysvo, but sales still hit $515 million in the fourth quarter.

Pfizers rivals for the COVID-19, RSV and pneumococcal markets feature in the chasing pack. Merck came in second on four of the five metrics, only slipping to third place behind Moderna on the reputation rank. Moderna and GSK fought for third place across the other categories. Sanofi was fifth on all the metrics.

Discussing opportunities open to manufacturers, ZoomRx said physicians look for players with a broad portfolio of vaccines that elicit strong responses and provide long-lived immunity for a large population. The analysts also see scope to gain ground by establishing patient assistance programs and working with healthcare professionals to increase access to vaccines.

Read more:

Pfizer takes top spot in docs' vaccine ranking by 'huge margin' - FiercePharma

Page 48«..1020..47484950..6070..»